EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local...

Area of Science:

• Uro-oncology
• Medical guidelines
• Prostate cancer management

Background:

• Clinically localized prostate cancer (PCa) requires updated management strategies.
• The European Association of Urology (EAU) and affiliated societies developed consensus guidelines.
• This paper summarizes the 2024 guidelines for localized PCa.

Purpose of the Study:

• To present a summary of the 2024 EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines.
• To cover screening, diagnosis, and treatment of localized prostate cancer.
• To provide updated recommendations based on recent evidence.

Main Methods:

• Literature review of English publications from May 2020 to 2023.
• Systematic review of evidence to update guidelines.
• Inclusion of strength ratings for each recommendation.

Main Results:

• Recommends risk-adapted screening starting at age 50, based on life expectancy.
• Highlights multiparametric MRI to avoid unnecessary biopsies; recommends targeted and regional biopsies.
• Identifies PSMA PET as the most sensitive imaging for metastatic spread; supports active surveillance for low-risk PCa and selected intermediate-risk cases (ISUP Grade Group 2).

Conclusions:

• Evidence for localized PCa diagnosis, staging, and treatment is rapidly evolving.
• The guidelines underscore the multidisciplinary nature of PCa management.
• Updated guidelines provide a framework for evidence-based, individualized patient care.